Dominique Lorcy

Prof. Dominique Lorcy

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2018 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
YGYann Le Gal
Yann Le Gal
TRThierry Roisnel
Thierry Roisnel
PAPascale Auban-Senzier
Pascale Auban-Senzier
NBNathalie Bellec
Nathalie Bellec
JÍJorge Íñiguez
Jorge Íñiguez
DLDominique Lorcy
Dominique Lorcy

22 March 2018 in Inorganic Chemistry
Verified
Journal Article
Closed access
ABAmandine Boulmier
Amandine Boulmier
AVAntoine Vacher
Antoine Vacher
DZDejin Zang
Dejin Zang
SYShu Yang
Shu Yang
ASAli Saad
Ali Saad
ADAnne Dolbecq
Anne Dolbecq

8 October 2018 in Journal of Applied Physics
Verified
Journal Article
Closed access
PDF file
CAColine Adda
Coline Adda
BCBenoit Corraze
Benoit Corraze
PSPablo Stoliar
Pablo Stoliar
PDPascale Diener
Pascale Diener
JTJulien Tranchant
Julien Tranchant
LCLaurent Cario
Laurent Cario
A major challenge in the field of neurocomputing is to mimic the brain's behavior by implementing artificial synapses and neurons directly in hardware. Toward that purpose, many researchers are exploring the potential of new materials and new physical phenomena. Recently, a new concept of the Leaky Integrate and Fire (LIF) artificial neuron was proposed based on the electric Mott transition in the inorganic Mott insulator GaTa4Se8. In this work, we report on the LIF behavior in simple two-terminal devices in three chemically very different compounds, the oxide (V0.89Cr0.11)2O3, the sulfide GaMo4S8, and the molecular system [Au(iPr-thiazdt)2] (C12H14AuN2S8), but sharing a common feature, their Mott insulator ground state. In all these devices, the application of an electric field induces a volatile resistive switching and a remarkable LIF behavior under a train of pulses. It suggests that the Mott LIF neuron is a general concept that can be extended to the large class of Mott insulators.

28 August 2004 in Chemical Reviews
Verified
Journal Article
Closed access
DLDominique Lorcy
Dominique Lorcy
NBN. Bellec
N. Bellec

30 July 2014 in Inorganic Chemistry
Verified
Journal Article
Closed access
AFAgathe Filatre-Furcate
Agathe Filatre-Furcate
NBNathalie Bellec
Nathalie Bellec
OJOlivier Jeannin
Olivier Jeannin
PAPascale Auban-Senzier
Pascale Auban-Senzier
MFMarc Fourmigué
Marc Fourmigué
DLDominique Lorcy
Dominique Lorcy

11 May 2020 in Metallomics
Verified
Journal Article
Closed access
PDF file
DFDiana Fontinha
Diana Fontinha
Sílvia A. SousaSílvia A. Sousa
Sílvia A. Sousa
Tânia S. MoraisTânia S. Morais
Tânia S. Morais
Miguel PrudêncioMiguel Prudêncio
Miguel Prudêncio
Jorge LeitãoJorge Leitão
Jorge Leitão
FMFernanda Marques
Fernanda Marques
The anticancer, antimicrobial and antiplasmodial activities of six gold(iii) bis(dithiolene) complexes were studied. Complexes 1–6 showed relevant anticancer properties against A2780/A2780cisR ovarian cancer cells (IC50 values of 0.08–2 μM), also being able to overcome cisplatin resistance in A2780cisR cells. Complex 1 also exhibited significant antimicrobial activity against Staphylococcus aureus (minimum inhibitory concentration (MIC) values of 12.1 ± 3.9 μg mL−1) and both Candida glabrata and Candida albicans (MICs of 9.7 ± 2.7 and 19.9 ± 2.4 μg mL−1, respectively). In addition, all complexes displayed antiplasmodial activity against the Plasmodium berghei parasite liver stages, even exhibiting better results than the ones obtained using primaquine, an anti-malarial drug. Mechanistic studies support the idea that thioredoxin reductase, but not DNA, is a possible target of these complexes. Complex 1 is stable under biological conditions, which would be important if this compound is ever to be considered as a drug. Overall, the results obtained evidenced the promising biological activity of complex 1, which might have potential as a novel anticancer, antimicrobial and antiplasmodial agent to be used as an alternative to current therapeutics.